BIAF

bioAffinity Technologies, Inc.

HealthcareMedical - Diagnostics & ResearchUSUSDPeers →

$1.64

LiveJun 11, 2026

AI Brief

Market cap

$7.44M

52w range

0.69 – 13.80

P / E

—

EPS

—

Volume

116.73K

Revenue · FY

—

Overview Fundamentals Market Narrative & AI

Ratios Multiples Profile

Explain this page

Arphra AIPlain-English read on bioAffinity Technologies, Inc.’s valuation

Business description

· company · SEC profile

bioAffinity Technologies, Inc.

As a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer. Its portfolio features CyPath lung, a specialized diagnostic test designed for the early identification of lung cancer. Beyond diagnostics, the firm actively explores targeted therapies intended to combat cancer at a cellular level. This San Antonio, Texas-based company commenced operations in 2014.

Founded

—

IPO

Sep 01, 2022

Employees

San Antonio, TX

CEO

Maria Zannes

CFO

—

Exchange

NASDAQ

Fiscal year

—

Identifiers

· company_identifiers

CIK0001712762

CUSIP09076W307

ISINUS09076W3079

FIGIBIAF US

LEI—

Cross-listings

· companies · ISIN

BIAFPrimaryNasdaq Stock MarketusUSD$6.89M
BIAFWNasdaq Stock MarketusUSD$707.55K

The global universe keeps only the primary listing; the other venues for this security are shown here.